Puma Biotechnology | PBYI - Operating Profit


Puma Biotechnology reported $22.08M in Operating Profit for its fiscal quarter ending in September of 2024.





Operating Profit Change Date
Agios Pharmaceuticals USD -110.02M 11.55M Mar/2026
Alnylam Pharmaceuticals USD 137.59M 108.19M Mar/2026
Amgen USD 3.83B 130M Mar/2026
Biogen USD 514.3M 128.8M Mar/2026
BioMarin Pharmaceutical USD 129.65M 68.74M Mar/2026
Daiichi Sankyo JPY 89.54B 42.01B Dec/2025
Esperion Therapeutics USD 85.23M 95.19M Dec/2025
Exelixis USD 251.34M 15.43M Mar/2026
Gilead Sciences USD 2.68B 284M Mar/2026
Glaxosmithkline GBP 2.3B 1.46B Dec/2025
Incyte USD 324.17M 59.7M Mar/2026
MacroGenics USD -12.1M 30.74M Dec/2025
Moderna USD -1.39B 531M Mar/2026
Novartis USD 4.24B 171M Mar/2026
Pfizer USD 4.99B 340M Mar/2026
PTC Therapeutics USD 45.89M 127.51M Mar/2026
Puma Biotechnology USD 22.08M 24.26M Sep/2024
Regeneron Pharmaceuticals USD 744.8M 153.8M Mar/2026
Roche Holding CHF 9.56B 3.8B Dec/2025
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Sarepta Therapeutics USD 358.43M 768.52M Mar/2026
Takeda JPY -13.62B 182.44B Mar/2026
TG Therapeutics USD 34.8M 15.7M Mar/2026
Ultragenyx Pharmaceutical USD -216M 102M Mar/2026
Vanda Pharmaceuticals USD -40.66M 29.66M Dec/2024
Vertex Pharmaceuticals USD 1.14B 124.5M Mar/2026